Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 8207058, 14 pages
https://doi.org/10.1155/2018/8207058
Review Article

The Role of Cardiokines in Heart Diseases: Beneficial or Detrimental?

1Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China
2Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China
3Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China

Correspondence should be addressed to Ling Yang; nc.anis@gnilgnayzc and Chun Yang; moc.anis@ztnuhcgnay

Received 30 November 2017; Revised 19 January 2018; Accepted 7 February 2018; Published 18 March 2018

Academic Editor: Rei Shibata

Copyright © 2018 Ye-Shun Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. A. Wilmot, M. O'Flaherty, S. Capewell, E. S. Ford, and V. Vaccarino, “Coronary heart disease mortality declines in the United States from 1979 through 2011: Evidence for stagnation in young adults, especially women,” Circulation, vol. 132, no. 11, pp. 997–1002, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Nicholson, S. R. Gandra, R. J. Halbert, A. Richhariya, and R. J. Nordyke, “Patient-level costs of major cardiovascular conditions: A review of the international literature,” ClinicoEconomics and Outcomes Research, vol. 8, pp. 495–506, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Sudoh, K. Kangawa, N. Minamino, and H. Matsuo, “A new natriuretic peptide in porcine brain,” Nature, vol. 332, no. 6159, pp. 78–81, 1988. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. de Bold, H. B. Borenstein, A. T. Veress, and H. Sonnenberg, “A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 403–409, 1981. View at Google Scholar
  5. T. Sudoh, N. Minamino, K. Kangawa, and H. Matsuo, “C-Type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain,” Biochemical and Biophysical Research Communications, vol. 168, no. 2, pp. 863–870, 1990. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Doroudgar and C. C. Glembotski, “The cardiokine story unfolds: Ischemic stress-induced protein secretion in the heart,” Trends in Molecular Medicine, vol. 17, no. 4, pp. 207–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Planavila, J. Fernández-Solà, and F. Villarroya, “Cardiokines as Modulators of Stress-Induced Cardiac Disorders,” Advances in Protein Chemistry and Structural Biology, vol. 108, pp. 227–256, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Shimano, N. Ouchi, and K. Walsh, “Cardiokines: recent progress in elucidating the cardiac secretome,” Circulation, vol. 126, no. 21, pp. e327–e332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Kobalava, “SP 04-1 the role of natriuretic peptides in the pathogenesis of cardiovascular diseases,” Journal of Hypertension, vol. 34, Suppl 1, p. e377, 2016, ISH 2016 Abstract Book. View at Publisher · View at Google Scholar
  10. P. K. Santhekadur, D. P. Kumar, M. Seneshaw, F. Mirshahi, and A. J. Sanyal, “The multifaceted role of natriuretic peptides in metabolic syndrome,” Biomedicine & Pharmacotherapy, vol. 92, pp. 826–835, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. T. I. Chang, J. Yang, J. V. Freeman, M. A. Hlatky, and A. S. Go, “Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease,” Journal of Cardiac Failure, vol. 19, no. 3, pp. 176–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Tonne, J. M. Campbell, A. Cataliotti et al., “Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes,” Clinical Chemistry, vol. 57, no. 6, pp. 864–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. B. K. Huntley, S. M. Sandberg, D. M. Heublein, S. Jeson Sangaralingham, J. C. Burnett, and T. Ichiki, “ProB-type natriuretic peptide-1-108 processing and degradation in human heart failure,” Circulation: Heart Failure, vol. 8, no. 1, pp. 89–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. B. M. Everett, T. Zeller, R. J. Glynn, P. M. Ridker, and S. Blankenberg, “High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention impact of statin therapy,” Circulation, vol. 131, no. 21, pp. 1851–1860, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Godkar, K. Bachu, B. Dave, S. Niranjan, and A. Khanna, “B-type natriuretic peptide (BNP) and ProBNP: Role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders,” American Journal of Therapeutics, vol. 15, no. 2, pp. 150–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. C. Wong, J. Guo, and A. Zhang, “The renal and cardiovascular effects of natriuretic peptides,” Advances in Physiology Education, vol. 41, no. 2, pp. 179–185, 2017. View at Publisher · View at Google Scholar
  17. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the american college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society,” Circulation, vol. 112, no. 12, pp. e154–e235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Mueller, “Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure [7],” Clinical Chemistry, vol. 53, no. 9, pp. 1719-1720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. G. Semenov and A. G. Katrukha, “Analytical Issues with Natriuretic Peptides - has this been Overly Simplified?” EJIFCC, vol. 27, no. 3, pp. 189–207, 2016. View at Google Scholar
  20. C. P. Y. Chan and T. H. Rainer, “Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome,” Advances in Clinical Chemistry, vol. 59, pp. 23–63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Halaris, “Inflammation, Heart Disease, and Depression,” Current Psychiatry Reports, vol. 15, no. 10, p. 400, 2013. View at Publisher · View at Google Scholar
  22. N. G. Frangogiannis, “Regulation of the inflammatory response in cardiac repair,” Circulation Research, vol. 110, no. 1, pp. 159–173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. M. Ciccone, F. Cortese, M. Gesualdo et al., “A novel cardiac bio-marker: ST2: a review,” Molecules, vol. 18, no. 12, pp. 15314–15328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. O. Weinberg, M. Shimpo, G. W. De Keulenaer et al., “Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction,” Circulation, vol. 106, no. 23, pp. 2961–2966, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Lax, J. Sanchez-Mas, M. C. Asensio-Lopez et al., “Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction,” JACC: Heart Failure, vol. 3, no. 1, pp. 50–58, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. R. R. Sun, L. Lu, M. Liu et al., “Biomarkers and heart disease,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 19, pp. 2927–2935, 2014. View at Google Scholar
  27. C. W. Yancy, M. Jessup, B. Bozkurt et al., “ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines,” Journal of the American College of Cardiology, vol. 62, no. 16, pp. e147–e239, 2013. View at Google Scholar
  28. W. M. Ansari, S. E. Humphries, A. K. Naveed, O. J. Khan, D. A. Khan, and E. H. Khattak, “Effect of Coronary Artery Disease risk SNPs on serum cytokine levels and cytokine imbalance in Premature Coronary Artery Disease,” Cytokine, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Tu, S. Nie, Y. Liao et al., “The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population,” American Journal of Human Genetics, vol. 93, no. 4, pp. 652–660, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. O. Hambrock, B. Kaufmann, S. Müller et al., “Structural characterization of TSC-36/Flik: Analysis of two charge isoforms,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 11727–11735, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. D. Anastasilakis, D. Koulaxis, N. Kefala et al., “Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy,” Metabolism - Clinical and Experimental, vol. 73, pp. 1–8, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Shimano, N. Ouchi, K. Nakamura et al., “Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 43, pp. E899–E906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Maruyama, K. Nakamura, K. N. Papanicolaou et al., “Follistatin‐like 1 promotes cardiac fibroblast activation and protects the heart from rupture,” EMBO Molecular Medicine, vol. 8, no. 8, pp. 949–966, 2016. View at Publisher · View at Google Scholar
  34. K. Wei, V. Serpooshan, C. Hurtado et al., “Epicardial FSTL1 reconstitution regenerates the adult mammalian heart,” Nature, vol. 525, no. 7570, pp. 479–485, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. A.-K. Alteköester and R. P. Harvey, “Bioengineered FSTL1 Patches Restore Cardiac Function Following Myocardial Infarction,” Trends in Molecular Medicine, vol. 21, no. 12, pp. 731–733, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. A. El-Armouche, N. Ouchi, K. Tanaka et al., “Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling,” Circulation: Heart Failure, vol. 4, no. 5, pp. 621–627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Tanaka, M. Valero-Muñoz, R. M. Wilson et al., “Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction,” JACC: Basic to Translational Science, vol. 1, no. 4, pp. 207–221, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Ogura, N. Ouchi, K. Ohashi et al., “Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models,” Circulation, vol. 126, no. 14, pp. 1728–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Lü, J. H. Liu, L. K. Zhang et al., “Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells,” Chinese Medical Journal, vol. 123, no. 23, pp. 3417–3421, 2010. View at Google Scholar
  40. X.-L. Lin, X.-L. He, J.-F. Zeng et al., “FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARγ-LXRα pathway in THP1 macrophage-derived foam cells,” DNA and Cell Biology, vol. 33, no. 8, pp. 514–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Yie, W. Wang, L. Deng et al., “Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling,” Chemical Biology & Drug Design, vol. 79, no. 4, pp. 398–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Fernández-Solà and A. P. Porta, “New treatment strategies for alcohol-induced heart damage,” International Journal of Molecular Sciences, vol. 17, no. 10, article no. 1651, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Planavila, I. Redondo, E. Hondares et al., “Fibroblast growth factor 21 protects against cardiac hypertrophy in mice,” Nature Communications, vol. 4, article 2019, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Planavila, I. Redondo-Angulo, F. Ribas et al., “Fibroblast growth factor 21 protects the heart from oxidative stress,” Cardiovascular Research, vol. 106, no. 1, pp. 19–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Patel, R. Adya, J. Chen et al., “Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts,” PLoS ONE, vol. 9, no. 2, Article ID e87102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Malekar, M. Hagenmueller, A. Anyanwu et al., “Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling,” Hypertension, vol. 55, no. 4, pp. 939–945, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. V. A. M. Van De Schans, S. W. M. Van Den Borne, A. E. Strzelecka et al., “Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy,” Hypertension, vol. 49, no. 3, pp. 473–480, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Marinou, C. Christodoulides, C. Antoniades, and M. Koutsilieris, “Wnt signaling in cardiovascular physiology,” Trends in Endocrinology & Metabolism, vol. 23, no. 12, pp. 628–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. E. T. Askevold, P. Aukrust, S. H. Nymo et al., “The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure,” Journal of Internal Medicine, vol. 275, no. 6, pp. 621–630, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Ueland, K. Caidahl, E. T. Askevold, T. Karlsson, M. Hartford, and P. Aukrust, “Secreted Frizzled-Related Protein 3 (sFRP3) in acute coronary syndromes,” International Journal of Cardiology, vol. 190, no. 1, pp. 217–219, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Lin, M. Angeli, K. J. Chung, C. Ejimadu, A. R. Rosa, and T. Lee, “sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: Differential roles in cell growth, energy metabolism, and extracellular matrix remodeling,” American Journal of Physiology-Cell Physiology, vol. 311, no. 5, pp. C710–C719, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Martin, H. Lin, C. Ejimadu, and T. Lee, “CALL FOR PAPERS Cell Signaling: Proteins, Pathways and Mechanisms Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts,” American Journal of Physiology-Cell Physiology, vol. 309, no. 3, pp. C139–C147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. W. He, L. Zhang, A. Ni et al., “Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 107, no. 49, pp. 21110–21115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Mastri, Z. Shah, K. Hsieh et al., “Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention,” American Journal of Physiology-Cell Physiology, vol. 306, no. 6, pp. C531–C539, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. N. H. Dayawansa, X.-M. Gao, D. A. White, A. M. Dart, and X.-J. Du, “Role of MIF in myocardial ischaemia and infarction: Insight from recent clinical and experimental findings,” Clinical Science, vol. 127, no. 3, pp. 149–161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. P. V. Tilstam, D. Qi, L. Leng, L. Young, and R. Bucala, “MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics,” Expert Opinion on Therapeutic Targets, vol. 21, no. 7, pp. 671–683, 2017. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Chan, D. A. White, X. Wang et al., “Macrophage Migration Inhibitory Factor for the Early Prediction of Infarct Size,” Journal of the American Heart Association, vol. 2, no. 5, p. e000226, 2013. View at Publisher · View at Google Scholar
  58. J.-Y. Luo, R. Xu, X.-M. Li et al., “MIF Gene Polymorphism rs755622 Is Associated With Coronary Artery Disease and Severity of Coronary Lesions in a Chinese Kazakh Population: A Case-Control Study,” Medicine, vol. 95, no. 4, p. e2617, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. D. A. White, Y. Su, P. Kanellakis et al., “Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 69, pp. 32–42, 2014. View at Publisher · View at Google Scholar
  60. A. Kirabo, S. Ryzhov, M. Gupte et al., “Neuregulin-1β induces proliferation, survival and paracrine signaling in normal human cardiac ventricular fibroblasts,” Journal of Molecular and Cellular Cardiology, vol. 105, pp. 59–69, 2017. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Hedhli, Q. Huang, A. Kalinowski et al., “Endothelium-derived neuregulin protects the heart against ischemic injury,” Circulation, vol. 123, no. 20, pp. 2254–2262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. J. D. Gardner, “Neuregulin-1β as a potential therapeutic for targeting fibroblasts in heart disease,” Journal of Molecular and Cellular Cardiology, vol. 112, pp. 132-133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Krzeminski, “The Role of Adrenomedullin in Cardiovascular Response to Exercise - A Review,” Journal of Human Kinetics, vol. 53, no. 1, pp. 127–142, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. B. M. Y. Cheung and F. Tang, “Adrenomedullin: exciting new horizons,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 6, no. 1, pp. 4–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Beygui, P. S. Wild, T. Zeller et al., “Adrenomedullin and arterial stiffness integrative approach combining monocyte adm expression, plasma MR-Pro-ADM, and genome-wide association study,” Circulation: Cardiovascular Genetics, vol. 7, no. 5, pp. 634–641, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. H. K. Wong, T. T. Cheung, and B. M. Cheung, “Adrenomedullin and cardiovascular diseases,” Journal of the Royal Society of Medicine Cardiovascular Disease, vol. 1, no. 5, 2012. View at Google Scholar
  67. H. Nishida, T. Horio, Y. Suzuki et al., “Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin,” Peptides, vol. 29, no. 4, pp. 599–605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Tolppanen, M. Rivas-Lasarte, J. Lassus et al., “Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock,” Annals of Intensive Care, vol. 7, no. 1, article no. 6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  69. I. T. Klip, A. A. Voors, S. D. Anker et al., “Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction,” Heart, vol. 97, no. 11, pp. 892–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. R. J. A. Frost and S. Engelhardt, “A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart,” Circulation, vol. 116, no. 16, pp. 1768–1775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. G. G. J. Hazell, A. M. G. Peachey, J. E. Teasdale et al., “PI16 is a shear stress and inflammation-regulated inhibitor of MMP2,” Scientific Reports, vol. 6, Article ID 39553, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Tadimalla, P. J. Belmont, D. J. Thuerauf et al., “Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart,” Circulation Research, vol. 103, no. 11, pp. 1249–1258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. C. C. Glembotski, D. J. Thuerauf, C. Huang, J. A. Vekich, R. A. Gottlieb, and S. Doroudgar, “Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion,” The Journal of Biological Chemistry, vol. 287, no. 31, pp. 25893–25904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. C. C. Glembotski, “Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 512–517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Liu, C. Yu, H. Yu et al., “Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis,” Herz, pp. 1–6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Joki, K. Ohashi, D. Yuasa et al., “Neuron-derived neurotrophic factor ameliorates adverse cardiac remodeling after experimental myocardial infarction,” Circulation: Heart Failure, vol. 8, no. 2, pp. 342–351, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Pius-Sadowska and B. Machaliński, “BDNF – A key player in cardiovascular system,” Journal of Molecular and Cellular Cardiology, vol. 110, pp. 54–60, 2017. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Feng, S. Huke, G. Zhu et al., “Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation,” Proceeding of the National Academy of Sciences of the United States of America, vol. 112, no. 6, pp. 1880–1885, 2015. View at Google Scholar
  79. T. Brandenburger, H. Grievink, N. Heinen et al., “Effects of remote ischemic preconditioning and myocardial ischemia on microRNA-1 expression in the rat heart in vivo,” Shock (Augusta, Ga.), vol. 42, no. 3, pp. 234–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Anastasia, K. Deinhardt, S. Wang et al., “Trkb signaling in pericytes is required for cardiac microvessel stabilization,” PLoS ONE, vol. 9, no. 1, Article ID e87406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. Q. Liu and M. T. T. Wong-Riley, “Postnatal development of brain-derived neurotrophic factor (BDNF) and tyrosine protein kinase B (TrkB) receptor immunoreactivity in multiple brain stem respiratory-related nuclei of the rat,” Journal of Comparative Neurology, vol. 521, no. 1, pp. 109–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Shen, J. Morton, S. T. Davidge, and Z. Kassiri, “Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin II-induced hypertension and end-organ damage,” Journal of Molecular and Cellular Cardiology, vol. 103, pp. 11–21, 2017. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Chen, R. Li, R. S. Ross, and A. M. Manso, “Integrins and integrin-related proteins in cardiac fibrosis,” Journal of Molecular and Cellular Cardiology, vol. 93, pp. 162–174, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. Y.-H. Zhang, H.-Y. Sun, K.-H. Chen et al., “Evidence for functional expression of TRPM7 channels in human atrial myocytes,” Basic Research in Cardiology, vol. 107, no. 5, article no. 282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. M. George, A. Vijayakumar, S. B. Dhanesh, J. James, and K. Shivakumar, “Molecular basis and functional significance of Angiotensin II-induced increase in Discoidin Domain Receptor 2 gene expression in cardiac fibroblasts,” Journal of Molecular and Cellular Cardiology, vol. 90, pp. 59–69, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Xie, R. Tubbs, and B. Yang, “Detection of MGMT promoter methylation in glioblastoma using pyrosequencing,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp. 10216–10227, 2015. View at Google Scholar
  87. Y. S. Choi, A. B. M. de Mattos, D. Shao et al., “Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion,” Journal of Molecular and Cellular Cardiology, vol. 100, pp. 64–71, 2016. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Pöss, C. Ukena, I. Kindermann et al., “Angiopoietin-2 and outcome in patients with acute decompensated heart failure,” Clinical Research in Cardiology, vol. 104, no. 5, pp. 380–387, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Chen, L. Guo, B. Chen, L. Sun, and M. Cui, “Association of serum angiopoietin-1, angiopoietin-2 and angiopoietin-2 to angiopoietin-1 ratio with heart failure in patients with acute myocardial infarction,” Experimental and Therapeutic Medicine, vol. 5, no. 3, pp. 937–941, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Lukasz, G. Beutel, P. Kümpers et al., “Angiopoietin-2 in Adults with Congenital Heart Disease and Heart Failure,” PLoS ONE, vol. 8, no. 6, Article ID e66861, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Lu, F. Liu, F. Chen et al., “Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats,” Biomedicine & Pharmacotherapy, vol. 83, pp. 330–339, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Toldo, E. Mezzaroma, B. W. Van Tassell et al., “Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse,” Experimental Physiology, vol. 98, no. 3, pp. 734–745, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. A. B. Gustafsson and L. L. Brunton, “Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1β and NO: Role of cGMP-stimulated PDE2,” American Journal of Physiology-Cell Physiology, vol. 283, no. 2, pp. C463–C471, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. Å. B. Gustafsson and L. L. Brunton, “β-Adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1β via message stabilization,” Molecular Pharmacology, vol. 58, no. 6, pp. 1470–1478, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. E. T. Askevold, L. Gullestad, C. P. Dahl, A. Yndestad, T. Ueland, and P. Aukrust, “Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure,” Current Heart Failure Reports, vol. 11, no. 2, pp. 146–155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Schuett, R. Oestreich, G. H. Waetzig et al., “Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 2, pp. 281–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. L. De Gennaro, N. D. Brunetti, D. Montrone, F. De Rosa, A. Cuculo, and M. Di Biase, “Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction,” Inflammation, vol. 35, no. 1, pp. 363–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. O. M. Bhat, P. U. Kumar, N. V. Giridharan, D. Kaul, M. J. M. Kumar, and V. Dhawan, “Interleukin-18-induced atherosclerosis involves CD36 and NF-κB crosstalk in Apo E-/- mice,” Journal of Cardiology, vol. 66, no. 1, pp. 28–35, 2015. View at Publisher · View at Google Scholar · View at Scopus
  99. T. B. Opstad, H. Arnesen, A. Å. Pettersen, and I. Seljeflot, “Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study,” Metabolic Syndrome and Related Disorders, vol. 14, no. 5, pp. 242–248, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Y. Park and T. H. Heo, “Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis,” Cardiovasc Ther, 2017. View at Google Scholar
  101. V. N. Nikolic, T. Jevtovic-Stoimenov, D. Stokanovic et al., “An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure,” Journal of Cardiology, vol. 62, no. 1, pp. 37–43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Savic-Radojevic, S. Radovanovic, T. Pekmezovic et al., “The Role of Serum VCAM-1 and TNF-α as Predictors of Mortality and Morbidity in Patients with Chronic Heart Failure,” Journal of Clinical Laboratory Analysis, vol. 27, no. 2, pp. 105–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. S. D. Francis Stuart, N. M. De Jesus, M. L. Lindsey, and C. M. Ripplinger, “The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 91, pp. 114–122, 2016. View at Publisher · View at Google Scholar · View at Scopus
  104. D. J. Duncan, Z. Yang, P. M. Hopkins, D. S. Steele, and S. M. Harrison, “TNF-α and IL-1β increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes,” Cell Calcium, vol. 47, no. 4, pp. 378–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. D. J. Greensmith and M. Nirmalan, “The effects of tumor necrosis factor-alpha on systolic and diastolic function in rat ventricular myocytes,” Physiological Reports, vol. 1, no. 4, p. e00093, 2013. View at Publisher · View at Google Scholar
  106. C.-K. Wu, J.-K. Lee, F.-T. Chiang et al., “Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase,” Critical Care Medicine, vol. 39, no. 5, pp. 984–992, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Wang, H. Wang, Y. Zhang, H. Gao, S. Nattel, and Z. Wang, “Impairment of HERG K+ channel function by tumor necrosis factor-α: role of reactive oxygen species as a mediator,” The Journal of Biological Chemistry, vol. 279, no. 14, pp. 13289–13292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. S. E. Sawaya, Y. S. Rajawat, T. G. Rami et al., “Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 292, no. 3, pp. H1561–H1567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Richter, H.-J. Lautze, T. Walther, T. Braun, S. Kostin, and T. Kubin, “The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation,” The Journal of Heart and Lung Transplantation, vol. 34, no. 9, article no. 6047, pp. 1211–1214, 2015. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Hao, X. Li, Q. Li et al., “FGF23 promotes myocardial fibrosis in mice through activation of β-catenin,” Oncotarget , vol. 7, no. 40, pp. 64649–64664, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” The Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. B. Kestenbaum, M. C. Sachs, A. N. Hoofnagle et al., “Fibroblast growth factor-23 and cardiovascular disease in the general population the multi-ethnic study of atherosclerosis,” Circulation: Heart Failure, vol. 7, no. 3, pp. 409–417, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. R. Jimbo, F. Kawakami-Mori, S. Mu et al., “Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency,” Kidney International, vol. 85, no. 5, pp. 1103–1111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. V. Olsen, L. E. Rohde, L. Beck-da-Silva et al., “QRS widening rates and genetic polymorphisms of matrix metalloproteinases in a cohort of patients with chronic heart failure,” Canadian Journal of Cardiology, vol. 30, no. 3, pp. 345–351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. M. L. Lindsey and R. Zamilpa, “Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction,” Cardiovascular Therapeutics, vol. 30, no. 1, pp. 31–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Quttainah, R. Al-Hejailan, S. Saleh et al., “Progression of matrixin and cardiokine expression patterns in an ovine model of heart failure and recovery,” International Journal of Cardiology, vol. 186, pp. 77–89, 2015. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Mishra, A. Srivastava, T. Mittal, N. Garg, and B. Mittal, “Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1668–1674, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Medamana, R. A. Clark, and J. Butler, “Platelet-derived growth factor in heart failure,” Handbook of Experimental Pharmacology, vol. 243, pp. 355–369, 2017. View at Publisher · View at Google Scholar · View at Scopus
  119. D. Yang, J. Yuan, G. Liu et al., “Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1 /nuclear factor-kappa B axis,” International Journal of Medical Sciences, vol. 10, no. 7, pp. 812–824, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. W. Zhao, T. Zhao, V. Huang, Y. Chen, R. A. Ahokas, and Y. Sun, “Platelet-derived growth factor involvement in myocardial remodeling following infarction,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 5, pp. 830–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Hye Kim, S. Gyu Park, W.-K. Kim, S. U. Song, and J.-H. Sung, “Functional regulation of adipose-derived stem cells by PDGF-D,” Stem Cells, vol. 33, no. 2, pp. 542–556, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. Q. Wu, X. Hou, J. Xia et al., “Emerging roles of PDGF-D in EMT progression during tumorigenesis,” Cancer Treatment Reviews, vol. 39, no. 6, pp. 640–646, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Christensen, A. J. Najy, M. Snyder, L. S. Movilla, and H.-R. C. Kim, “A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate,” International Journal of Radiation Oncology • Biology • Physics, vol. 88, no. 1, pp. 151–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. B. J. He, M.-L. A. Joiner, M. V. Singh et al., “Oxidation of CaMKII determines the cardiotoxic effects of aldosterone,” Nature Medicine, vol. 17, no. 12, pp. 1610–1618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. T. Kempf, A. Zarbock, C. Widera et al., “GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice,” Nature Medicine, vol. 17, no. 5, pp. 581–588, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. P. P. Rainer, S. Hao, D. Vanhoutte et al., “Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction,” Circulation Research, vol. 114, no. 8, pp. 1246–1257, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. J. A. Baán, Z. V. Varga, P. Leszek et al., “Myostatin and IGF-I signaling in end-stage human heart failure: A qRT-PCR study,” Journal of Translational Medicine, vol. 13, no. 1, article no. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  128. T. B. Dschietzig, “Myostatin - From the mighty mouse to cardiovascular disease and cachexia,” Clinica Chimica Acta, vol. 433, pp. 216–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Oshima, N. Ouchi, M. Shimano et al., “Activin a and follistatin-like 3 determine the susceptibility of heart to ischemic injury,” Circulation, vol. 120, no. 16, pp. 1606–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. C. Widera, E. Giannitsis, T. Kempf et al., “Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome,” Clinical Chemistry, vol. 58, no. 8, pp. 1233–1241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. K. D. Panse, L. E. Felkin, M. M. López-Olañeta et al., “Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes,” Journal of Cardiovascular Translational Research, vol. 5, no. 6, pp. 814–826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Shimano, N. Ouchi, K. Nakamura et al., “Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy,” The Journal of Biological Chemistry, vol. 286, no. 11, pp. 9840–9848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Frantz, K. Hu, A. Adamek et al., “Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction,” Basic Research in Cardiology, vol. 103, no. 5, pp. 485–492, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Ikeuchi, H. Tsutsui, T. Shiomi et al., “Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction,” Cardiovascular Research, vol. 64, no. 3, pp. 526–535, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. R. J. Akhurst and A. Hata, “Targeting the TGFβ signalling pathway in disease,” Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 790–811, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. Y. Yang, Y. Li, Z. Ma et al., “A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection,” Progress in Lipid Research, vol. 64, pp. 170–177, 2016. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Appari, A. Breitbart, F. Brandes et al., “C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure,” Circulation Research, vol. 120, no. 1, pp. 66–77, 2017. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Kambara, K. Ohashi, R. Shibata et al., “CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism,” The Journal of Biological Chemistry, vol. 287, no. 23, pp. 18965–18973, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. J. M. Peterson, Z. Wei, M. M. Seldin, M. S. Byerly, S. Aja, and G. W. Wong, “CTRP9 transgenic mice are protected from diet-induced obesity and metabolic dysfunction,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 305, no. 5, pp. R522–R533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Su, Y. Yuan, X.-M. Wang et al., “Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice,” Basic Research in Cardiology, vol. 108, article 315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. Y. Yuan, W. B. Lau, H. Su et al., “C1q-TNF-related protein-9, a novel cardioprotetcive cardiokine, requires proteolytic cleavage to generate a biologically active globular domain isoform,” American Journal of Physiology-Endocrinology and Metabolism, vol. 308, no. 10, pp. E891–E898, 2015. View at Publisher · View at Google Scholar · View at Scopus
  142. T. Kambara, R. Shibata, K. Ohashi et al., “C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism,” Molecular and Cellular Biology, vol. 35, no. 12, pp. 2173–2185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. K. K. Baskin, C. E. Grueter, C. M. Kusminski et al., “MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver,” EMBO Molecular Medicine, vol. 6, no. 12, pp. 1610–1621, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. J. W. S. Jahng, E. Song, and G. Sweeney, “Crosstalk between the heart and peripheral organs in heart failure,” Experimental & Molecular Medicine, vol. 48, no. 3, article no. e217, 2016. View at Publisher · View at Google Scholar · View at Scopus